PressRelease-1999-25

RESEARCH TRIANGLE PARK, N.C. - July 19, 1999 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today the acquisition, through its Innovex service group, of the business and assets of MediTrain, the Netherlands' leading multimedia pharmaceutical sales representative training company.

MediTrain, founded in 1992 by Managing Director Chris Kerkhof, is the only training provider which has Netherlands Pharmaceutical Association accreditation for all its sales representative training modules. MediTrain not only offers traditional outsourced training services but also has a number of innovative Internet-based and multimedia training products. These include multimedia-based examination and testing services that are unique to MediTrain. The company has an in-house staff of 5 people complemented by a substantial network of freelance trainers. MediTrain occupies offices in a purpose-built training center in Zeewolde, Netherlands.

The acquisition, which is being accounted for as a purchase transaction, was made in exchange for Quintiles stock and is expected to be neutral to Quintiles' earnings per share.

"The acquisition of a specialized sales training services organization expands our commercial solutions portfolio and offers further differentiation from our competitors," said Jim Mauzey, Chief Operating Officer of Quintiles' Innovex Division. "MediTrain provides Quintiles with an established, highly reputable and technologically advanced service provider whose capabilities and expertise can be marketed throughout Europe and elsewhere."

"Outsourcing of training is already well accepted by our customers," said Chris Kerkhof of MediTrain. "With over 70,000 industry-wide sales representatives in Europe and a high turnover rate within the sector, we believe that the opportunities are enormous. Forging this relationship with Quintiles opens the door to rapid geographic expansion within Europe and for the extension of our product offering into new areas of training and new target audiences."

Quintiles Transnational Corp. is the market leader in providing a full range of integrated product development and commercialization solutions to the pharmaceutical, biotechnology and medical device industries. Quintiles also is a leader in the electronic data interchange and healthcare informatics industry and provides healthcare policy consulting to governments and other organizations worldwide.

Headquartered near Research Triangle Park, North Carolina, Quintiles is a member of the Forbes Platinum 400, the Fortune 1000, the Business Week Global 1000 and the Nasdaq-100 Index. With more than 19,000 employees worldwide and offices in 31 countries, Quintiles operates through specialized work groups dedicated to meeting customers' individual needs.

Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risks that new products and features will not gain market acceptance, that revenues associated with new products and features will not be sufficient to offset costs or maintain the company's growth rate, actual operating performance, the ability to operate successfully in new lines of business and the ability to maintain large client contracts or to enter into new contracts. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.